From the publishers of JADPRO

DLBCL Resource Center

Advertisement
FROM THE EDITOR

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We've curated the most important information, education, and cutting-edge research on this disease state and created our own original resources to empower your practice. We're excited to provide this new offering, and we hope you and your colleagues find it valuable in helping your patients navigate DLBCL diagnosis, treatment, and survivorship. Take a look around, and send us your feedback at editor@advancedpractitioner.com

Lindsey Lyle, MS, PA-C

Ashley Ames, MSN, RN, FNP-BC, OCN
Oncology Nurse Practitioner
Memorial Sloan Kettering Cancer Center

News & Literature Highlights

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

OncoImmunology

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Cancers

Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Biologics: Targets and Therapies

Antibody therapies for large B-cell lymphoma

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

Leukemia

Treatment resistance in diffuse large B-cell lymphoma

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

2021 European Hematology Association Virtual Congress (Abstract)

Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other non-Hodgkin’s B-cell lymphomas - a phase 2 study

2021 American Society of Clinical Oncology Annual Meeting (Abstract)

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

2021 American Society of Clinical Oncology Annual Meeting (Abstract)

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Advertisement
Advertisement